Prediction of novel treatment options for venetoclax-resistant
AML cells based on drug repurposing.

Skip to top bar Skip to header Skip to content Skip to footer

Publications Detailed Information on Publication Record

Detailed Information on Publication Record

a 2022

Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN et. al.

Basic information

Original name

Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.

Authors

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA

Edition

Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland, 2022

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Central European Institute of Technology

Změněno: 20/1/2023 15:26, Bc. Kateřina Kolesová

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.

@proceedings{2248134,
   author = {Ladungová, Adriana and Buša, Daniel and Lodhi, Yusuf and Hýl, Jan and Čulen, Martin and Šmída, Michal},
   booktitle = {Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland},
   title = {Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.},
   year = {2022}
}

TY  - CONF
ID  - 2248134
AU  - Ladungová, Adriana - Buša, Daniel - Lodhi, Yusuf - Hýl, Jan - Čulen, Martin - Šmída, Michal
PY  - 2022
TI  - Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.
ER  -

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In \textit{Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland}. 2022.